Acute bilirubin ditaurate exposure attenuates ex vivo platelet reactive oxygen species production, granule exocytosis and activation

Abstract

Background Bilirubin, a by-product of haem catabolism, possesses potent endogenous antioxidant and platelet inhibitory properties. These properties may be useful in inhibiting inappropriate platelet activation and ROS production; for example, during storage for transfusion. Given the hydrophobicity of unconjugated bilirubin (UCB), we investigated the acute platelet inhibitory and ROS scavenging ability of a water-soluble bilirubin analogue, bilirubin ditaurate (BRT) on ex vivo platelet function to ascertain its potential suitability for inclusion during platelet storage. Methods The inhibitory potential of BRT (10–100 μM) was assessed using agonist induced platelet aggregation, dense granule exocytosis and flow cytometric analysis of P-selectin and GPIIb/IIIa expression. ROS production was investigated by analysis of H 2 DCFDA fluorescence following agonist simulation while mitochondrial ROS production investigated using MitoSOX™ Red. Platelet mitochondrial membrane potential and viability was assessed using TMRE and Zombie Green™ respectively. Results Our data shows ≤35 μM BRT significantly inhibits both dense and alpha granule exocytosis as measured by ATP release and P-selectin surface expression, respectively. Significant inhibition of GPIIb/IIIa expression was also reported upon ≤35 μM BRT exposure. Furthermore, platelet exposure to ≤10 μM BRT significantly reduces platelet mitochondrial ROS production. Despite the inhibitory effect of BRT, platelet viability, mitochondrial membrane potential and agonist induced aggregation were not perturbed. Conclusions These data indicate, for the first time, that BRT, a water-soluble bilirubin analogue, inhibits platelet activation and reduces platelet ROS production ex vivo and may, therefore, may be of use in preserving platelet function during storage.

Intrauterine Blood Plasma Platelet-Therapy Mitigates Persistent Breeding-Induced Endometritis, Reduces Uterine Infections, and Improves Embryo Recovery in Mares

“…Platelet viability was assessed using a full-spectrum detector based (filter-less) Cytek Aurora Flow Cytometer (Cytek Biosciences Inc., Fremont, CA, USA) adapted from protocols published elsewhere [ 62 , 63 ]. Immunolabeling of CD41/61, a platelet-specific antigen, was carried out with a primary (CD41/61, monoclonal antibody CO.35E4, #MA5-28370 Invitrogen, Life Technologies Corporation, Carlsbad, CA, USA) and a secondary antibody conjugated with a fluorochrome (goat polyclonal anti-mouse IgG conjugated with R-phycoerythrin; #P-852, Invitrogen, Life Technologies Corporation, OR, USA).…”

Heme Oxygenase Dependent Bilirubin Generation in Vascular Cells: A Role in Preventing Endothelial Dysfunction in Local Tissue Microenvironment?

“…Thus, although the different cell types exhibit varying degrees of sensitivity toward bilirubin toxicity, they all benefit from bilirubin cytoprotection at low concentrations. This has clinical implications, since recent research has shown that BRT prevents ROS generation in ex vivo platelets, opening the possibility of screening the actions of acute BRT treatment to improve platelets storage and function (Pennell et al, 2019).…”

Three Manual Noncommercial Methods to Prepare Equine Platelet-Rich Plasma

“…Platelet viability was assessed using a full-spectrum detector-based (filterless) Cytek Aurora Flow Cytometer (Cytek Biosciences Inc, Fremont, CA, USA) adapted from protocols published elsewhere [ 26 , 27 ]. Immunolabeling of CD41/61, a platelet-specific antigen, was carried out with a primary (#MA5-28,370 Invitrogen, Life Technologies Corporation, OR, USA) and a secondary antibody conjugated with a fluorochrome (#P-852, Invitrogen, Life Technologies Corporation, Carlsbad, CA, USA).…”